Mirikizumab Tops Placebo for Moderately-to-Severely Active Ulcerative Colitis

FRIDAY, July 7, 2023 -- For patients with moderately-to-severely active ulcerative colitis, mirikizumab is more effective than placebo for inducing and maintaining clinical remission, according to a study published in the June 29 issue of the New...